This study was supported by grants from National Natural Science Foundation of China (No.30370616 and No.30070335), and Eleventh Five-Year Project of the Armed Forces Outstanding Talent (No.06J019).
Background Gefitinib, an inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, is an effective treatment for epithelial tumors, including non-small cell lung cancer (NSCLC), and is generally well t...